Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1972 Sep;51(9):2331–2338. doi: 10.1172/JCI107044

An evaluation of antibodies and clinical resistance to salmon calcitonin

Frederick R Singer 1,2,3,4, J Phillip Aldred 1,2,3,4, Robert M Neer 1,2,3,4, Stephen M Krane 1,2,3,4, John T Potts 1,2,3,4, Kurt J Bloch 1,2,3,4
PMCID: PMC292399  PMID: 4674133

Abstract

21 patients with Paget's disease of bone and one with osteoporosis were studied to detect development of antibodies to salmon calcitonin during chronic therapy. Antibody titers ranged from 1:40 to 1:30,000 in plasma obtained after treatment of 11 patients. Radio-immunoelectrophoresis revealed that the antibodies were restricted to the γG class. One patient, W. O., with Paget's disease initially responded to treatment with a decrease in bone turnover, but later became resistant to the hormone in association with the appearance of a very high titer (1:30,000) of antibody against salmon calcitonin. A 1:10 dilution of his plasma was shown to completely inactivate 20 mMRC units/ml of salmon calcitonin as detected by bioassay in rats; slight inactivation was detected at a 1:200 dilution. All other patients continued to respond to salmon calcitonin despite the development of antibody to the hormone in ten cases. No evidence of systemic allergic reactions or other toxicity was found in any patient. The data suggest that although antibody formation may occur in as many as 50% of patients treated with salmon calcitonin, this antibody response is unlikely to be of clinical significance in most patients. However, in an occasional patient, a marked antibody response may occur which interferes with the therapeutic use of the hormone.

Full text

PDF
2331

Images in this article

2335Image
on p.2335

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERSON S. A., YALOW R. S., BAUMAN A., ROTHSCHILD M. A., NEWERLY K. Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J Clin Invest. 1956 Feb;35(2):170–190. doi: 10.1172/JCI103262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BERSON S. A., YALOW R. S. Quantitative aspects of the reaction between insulin and insulin-binding antibody. J Clin Invest. 1959 Nov;38:1996–2016. doi: 10.1172/JCI103979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bloch K. J., Morse H. C., 3rd, Austen K. F. Biologic properties of rat antibodies. I. Antigen-binding by four classes of anti-DNP antibodies. J Immunol. 1968 Oct;101(4):650–657. [PubMed] [Google Scholar]
  4. FAHEY J. L., MCLAUGHLIN C. PREPARATION OF ANTISERA SPECIFIC FOR 6.6 S GAMMA-GLOBULINS, BETA 2A-GLOBULINS, GAMMA-1.-MACROGLOBULINS, AND FOR TYPE I AND II COMMON GAMMA-GLOBULIN DETERMINANTS. J Immunol. 1963 Oct;91:484–497. [PubMed] [Google Scholar]
  5. Fleischer N., Abe K., Liddle G. W., Orth D. N., Nicholson W. E. ACTH antibodies in patients receiving depot porcine ACTH to hasten recovery from pituitary-adrenal suppression. J Clin Invest. 1967 Feb;46(2):196–204. doi: 10.1172/JCI105522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Foster G. V., Joplin G. F., MacIntyre I., Melvin K. E., Slack E. Effect of thyrocalcitonin in man. Lancet. 1966 Jan 15;1(7429):107–109. doi: 10.1016/s0140-6736(66)91255-4. [DOI] [PubMed] [Google Scholar]
  7. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  8. LAURELL C. B. ELECTROPHORETIC MICROHETEROGENEITY OF SERUM ALPHA-1-ANTITRYPSIN. Scand J Clin Lab Invest. 1965;17:271–274. doi: 10.1080/00365516509075347. [DOI] [PubMed] [Google Scholar]
  9. MACINTYRE I. Flame photometry. Adv Clin Chem. 1961;4:1–28. [PubMed] [Google Scholar]
  10. Melick R. A., Gill J. R., Jr, Berson S. A., Yalow R. S., Bartter F. C., Potts J. T., Jr, Aurbach G. D. Antibodies and clinical resistance to parathyroid hormone. N Engl J Med. 1967 Jan 19;276(3):144–147. doi: 10.1056/NEJM196701192760304. [DOI] [PubMed] [Google Scholar]
  11. Neher R., Riniker B., Maier R., Byfield P. G., Gudmundsson T. V., MacIntyre I. Human calcitonin. Nature. 1968 Dec 7;220(5171):984–986. doi: 10.1038/220984a0. [DOI] [PubMed] [Google Scholar]
  12. PARKER M. L., MARIZ I. K., DAUGHADAY W. H. RESISTANCE TO HUMAN GROWTH HORMONE IN PITUITARY DWARFISM: CLINICAL AND IMMUNOLOGIC STUDIES. J Clin Endocrinol Metab. 1964 Oct;24:997–1004. doi: 10.1210/jcem-24-10-997. [DOI] [PubMed] [Google Scholar]
  13. PRADER A., WAGNER H., SZEKY J., ILLIG R., TOUBER J. L., MAINGAY D. ACQUIRED RESISTANCE TO HUMAN GROWTH HORMONE CAUSED BY SPECIFIC ANTIBODIES. Lancet. 1964 Aug 22;2(7356):378–382. doi: 10.1016/s0140-6736(64)90390-3. [DOI] [PubMed] [Google Scholar]
  14. PROCKOP D. J., UDENFRIEND S. A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem. 1960 Nov;1:228–239. doi: 10.1016/0003-2697(60)90050-6. [DOI] [PubMed] [Google Scholar]
  15. ROTH J., GLICK S. M., YALOW R. S., BERSON S. A. ANTIBODIES TO HUMAN GROWTH HORMONE (HGH) IN HUMAN SUBJECTS TREATED WITH HGH. J Clin Invest. 1964 Jun;43:1056–1065. doi: 10.1172/JCI104989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rosselin G., Assan R., Yalow R. S., Berson S. A. Separation of antibody-bound and unbound peptide hormones labelled with iodine-131 by talcum powder and precipitated silica. Nature. 1966 Oct 22;212(5060):355–357. doi: 10.1038/212355a0. [DOI] [PubMed] [Google Scholar]
  17. Roth J., Glick S. M., Klein L. A., Petersen M. J. Specific antibody to vasopressin in man. J Clin Endocrinol Metab. 1966 Jun;26(6):671–675. doi: 10.1210/jcem-26-6-671. [DOI] [PubMed] [Google Scholar]
  18. Schlueter R. J., Aldred J. P., Fisher J. D. Thyrocalcitonin: bioassay characteristics of purified preparations. Acta Endocrinol (Copenh) 1968 Jun;58(2):268–276. doi: 10.1530/acta.0.0580268. [DOI] [PubMed] [Google Scholar]
  19. Waldmann T. A., Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1–110. doi: 10.1159/000385919. [DOI] [PubMed] [Google Scholar]
  20. Woodhouse N. J., Bordier P., Fisher M., Joplin G. F., Reiner M., Kalu D. N., Foster G. V., MacIntyre I. Human calcitonin in the treatment of Paget's bone disease. Lancet. 1971 Jun 5;1(7710):1139–1143. doi: 10.1016/s0140-6736(71)91657-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES